Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzydamine→

Benzydamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
642-72-8
Molecular formula
C19H23N3O
Molecular weight
309.4 g/mol
Drug class
Topical indazole anti-inflammatory and analgesiclocal anaesthetic activity
Mechanism of action
Acts mainly through local anti-inflammatory effects, including inhibition of pro-inflammatory cytokine synthesis (notably TNF-α and IL-1β), membrane stabilisation and reduced neutrophil oxidative/granule responses. It is only a weak cyclo-oxygenase/lipoxygenase inhibitor at higher concentrations and also has local anaesthetic activity.
Indications / reported uses
  • Short-term local relief of pain and inflammation in the mouth and throat, including sore throat, pharyngitis, tonsillitis, oral ulcers and inflammation following dental procedures; formulation-specific use applies

Sources: UK SmPC — Benzydamine 0.15% oromucosal spray · NHS medicine information — Benzydamine · Peer-reviewed pharmacology review (2025) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzydamine Environmental Risk Assessment (ERA) (the Benzydamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.